Latvia - Latvia - Zāļu valsts aģentūra

merus labs luxco ii s.a r.l., luxembourg - izosorbīda dinitrāts - ilgstošās darbības tablete - 20 mg

Latvia - Latvia - Zāļu valsts aģentūra

sanofi b.v., netherlands - imūbnglobulīns pret cilvēka timocītiem, truša - pulveris infūziju šķīduma pagatavošanai - 25 mg

Latvia - Latvia - Zāļu valsts aģentūra

neovii biotech gmbh, germany - imūbnglobulīns pret cilvēka t limfocītiem, dzīvnieka - koncentrāts infūziju šķīduma pagatavošanai - 20 mg/ml

Latvia - Latvia - Zāļu valsts aģentūra

merus labs luxco ii s.a r.l., luxembourg - izosorbīda dinitrāts - ilgstošās darbības tablete - 40 mg

Latvia - Latvia - Zāļu valsts aģentūra

sandoz d.d., slovenia - sildenafils - tablete - 100 mg

Latvia - Latvia - Zāļu valsts aģentūra

octapharma (ip) sprl, belgium - proteīns, cilvēka plazmas - Šķīdums infūzijām - 45-70 mg/ml

Kesatuan Eropah - Latvia - EMA (European Medicines Agency)

accord healthcare s.l.u. - lenalidomide - multiple mieloma - imūnsupresanti - multiple myelomalenalidomide accord as monotherapy is indicated for the maintenance treatment of adult patients with newly diagnosed multiple myeloma who have undergone autologous stem cell transplantation. lenalidomide accord as combination therapy with dexamethasone, or bortezomib and dexamethasone, or melphalan and prednisone (see section 4. 2) ir norādīts ārstēšanai pieaugušiem pacientiem ar iepriekš neārstētiem multiplā mieloma, kas nav tiesīgi transplantātu. lenalidomide vienojoties kopā ar deksametazona ir indicēts, lai ārstētu multiplā mieloma pieaugušo pacientiem, kuri ir saņēmuši vismaz vienu pirms terapijas. follicular lymphomalenalidomide accord in combination with rituximab (anti-cd20 antibody) is indicated for the treatment of adult patients with previously treated follicular lymphoma (grade 1 – 3a).

Kesatuan Eropah - Latvia - EMA (European Medicines Agency)

mylan ireland limited - lenalidomide - multiple mieloma - imūnsupresanti - multiple myelomalenalidomide mylan as monotherapy is indicated for the maintenance treatment of adult patients with newly diagnosed multiple myeloma who have undergone autologous stem cell transplantation. lenalidomide mylan as combination therapy with dexamethasone, or bortezomib and dexamethasone, or melphalan and prednisone is indicated for the treatment of adult patients with previously untreated multiple myeloma who are not eligible for transplant. lenalidomide mylan in combination with dexamethasone is indicated for the treatment of multiple myeloma in adult patients who have received at least one prior therapy. follicular lymphomalenalidomide mylan in combination with rituximab (anti-cd20 antibody) is indicated for the treatment of adult patients with previously treated follicular lymphoma (grade 1-3a).

Kesatuan Eropah - Latvia - EMA (European Medicines Agency)

lipomed gmbh - talidomīds - multiple mieloma - imūnsupresanti - thalidomide lipomed in combination with melphalan and prednisone is indicated as first line treatment of patients with untreated multiple myeloma, aged ≥ 65 years or ineligible for high dose chemotherapy. thalidomide lipomed is prescribed and dispensed in accordance with the thalidomide lipomed pregnancy prevention programme (see section 4.

Latvia - Latvia - Zāļu valsts aģentūra

apc pharmlog sp. z o.o., poland - sildenafils - apvalkotā tablete - 25 mg